| Bipolar Disorder (2018) |
1.56 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
| Bipolar Disorder or Schizophrenia |
3.11 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
| Neuroticism (Nagel 2018) |
1.40 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES SLC22A1 |
| Schizophrenia (2018) |
3.02 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
| Worry (Nagel 2018) |
1.02 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A1 |
| Breast Cancer |
2.39 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
CDKN2B CDKN2B-AS1 FES |
| Coronary Artery Disease (CAD) |
30.37 |
7 |
5 |
11.1 |
0.99 |
1.8e-06 |
ADAMTS7 CDKN2B CDKN2B-AS1 LPL PHACTR1 SLC22A3 TCF21 |
| HDL Cholesterol |
26.28 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
LPL SORT1 |
| LDL Cholesterol |
43.11 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
SORT1 |
| Schizophrenia (2014) |
2.94 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
| Triglycerides |
27.11 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
LPL |
| Type 2 Diabetes (T2D) (2012) |
3.88 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CDKN2B |
| Blood Eosinophil Count |
0.54 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
LPL |
| Blood Platelet Count |
0.83 |
4 |
1 |
2.2 |
0.72 |
1.7e-01 |
ADAMTS7 CDKN2B LPL SLC22A3 |
| Blood Red Count |
0.49 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES TCF21 |
| Blood White Count |
1.08 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
CDKN2B FES |
| Heel T-Score |
0.35 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SORT1 |
| BMI |
0.92 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
LPL SLC22A3 |
| Height |
0.78 |
4 |
3 |
6.7 |
-1.00 |
4.5e-03 |
FES LPL SLC22A3 SORT1 |
| Waist Hip Ratio (WHR) |
2.29 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
ADAMTS7 LPL SLC22A3 |
| Systolic Blood Pressure |
6.61 |
6 |
3 |
6.7 |
0.51 |
3.0e-01 |
ADAMTS7 FES PHACTR1 SLC22A1 SLC22A3 TCF21 |
| Smoking Status |
2.52 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
| Allergy or Eczema |
1.23 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
| Cardiovascular Disease |
9.86 |
6 |
5 |
11.1 |
0.94 |
4.6e-03 |
FES LPL SLC22A1 SLC22A3 SORT1 TCF21 |
| Respiratory disease |
1.37 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
| Type 2 Diabetes (T2D) (2018) |
2.18 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
LPL |
| Lung FEV1/FVC ratio |
1.11 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
RP11-378J18.8 SORT1 TCF21 |
| Lung FVC |
0.91 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
TCF21 |
| Neuroticism |
1.32 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A1 |
| Hair Pigment |
0.48 |
4 |
3 |
6.7 |
-0.79 |
2.1e-01 |
ADAMTS7 CDKN2B CDKN2B-AS1 FES |
| Hand grip strength (left) |
1.70 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES PHACTR1 |
| Number of treatments/medications taken |
4.45 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES LPL SORT1 |
| Sensitivity / hurt feelings |
1.84 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
| Systolic blood pressure, automated reading |
5.40 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES PHACTR1 |
| Angina |
32.99 |
11 |
10 |
22.2 |
1.00 |
5.9e-17 |
ADAMTS7 CDKN2B CDKN2B-AS1 FES LPL PHACTR1 RP11-378J18.8 SLC22A1 SLC22A3 SORT1 TCF21 |
| Medication: Metformin |
2.63 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
CDKN2B LPL |
| Pack years adult smoking proportion |
7.13 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ADAMTS7 |
| Impedance of leg (right) |
1.29 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
| Leg fat-free mass (left) |
1.03 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES SLC22A3 |
| Trunk fat percentage |
0.99 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A3 |
| Hand grip strength (right) |
1.31 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PHACTR1 |
| High blood pressure |
6.58 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES PHACTR1 TCF21 |
| Hayfever, allergic rhinitis or eczema |
1.35 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
| Multivitamins +/- minerals |
2.15 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADAMTS7 |
| Medication: Atenolol |
7.58 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
| Sitting height |
0.82 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADAMTS7 FES SLC22A3 |
| Chronic bronchitis/emphysema (father) |
4.71 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADAMTS7 |
| High blood pressure (mother) |
7.35 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES PHACTR1 |
| Impedance of leg (left) |
1.19 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES LPL |
| Leg predicted mass (left) |
1.03 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES SLC22A3 |
| Trunk fat mass |
1.07 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A3 |
| Number of incorrect matches in round |
1.47 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
| Past tobacco smoking |
2.07 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CDKN2B-AS1 |
| Alcohol usually taken with meals |
1.97 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
| Had menopause |
2.13 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
LPL |
| Heart attack |
25.57 |
10 |
8 |
17.8 |
0.98 |
2.5e-07 |
CDKN2B CDKN2B-AS1 FES LPL PHACTR1 RP11-378J18.8 SLC22A1 SLC22A3 SORT1 TCF21 |
| Allergy |
1.36 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
| Medication: Ramipril |
4.39 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
| Medication: Simvastatin |
15.80 |
8 |
3 |
6.7 |
0.91 |
1.6e-03 |
CDKN2B CDKN2B-AS1 FES LPL RP11-378J18.8 SLC22A1 SLC22A3 SORT1 |
| Illnesses of siblings |
3.45 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
| Weight |
0.95 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A3 |
| Impedance of arm (right) |
0.63 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CDKN2B |
| Arm fat percentage (right) |
1.22 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A3 |
| Trunk fat-free mass |
0.91 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A3 SORT1 |
| Hip circumference |
1.22 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
ADAMTS7 SLC22A3 |
| Father's age at death |
8.49 |
5 |
1 |
2.2 |
-1.00 |
2.5e-04 |
CDKN2B CDKN2B-AS1 FES LPL SORT1 |
| Pulse rate |
2.97 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
SLC22A1 TCF21 |
| Asthma |
0.93 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
| Medication: Ibuprofen (e.g. Nurofen) |
4.03 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
PHACTR1 SLC22A3 |
| Medication: Cholesterol lowering |
24.43 |
9 |
4 |
8.9 |
0.90 |
8.2e-04 |
CDKN2B CDKN2B-AS1 FES LPL RP11-378J18.8 SLC22A1 SLC22A3 SORT1 TCF21 |
| Lung cancer (father) |
4.66 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADAMTS7 |
| Illnesses of mother |
5.59 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
CDKN2B FES |
| Pulse wave Arterial Stiffness index |
3.34 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES PHACTR1 |
| Arm fat mass (right) |
1.08 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A3 |
| Trunk predicted mass |
0.89 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A3 SORT1 |
| Standing height |
0.73 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
SLC22A3 SORT1 |
| Breastfed as a baby |
1.67 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
| Hair/balding pattern: Pattern 4 |
1.17 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
| Birth weight of first child |
3.93 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES TCF21 |
| Peak expiratory flow (PEF) |
1.58 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
TCF21 |
| Medication: Paracetamol |
1.89 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
PHACTR1 |
| Headache pain in last month |
4.25 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES PHACTR1 |
| Medication for cholesterol, blood pressure or diabetes |
11.99 |
5 |
2 |
4.4 |
-0.96 |
1.0e-02 |
FES LPL SLC22A1 SORT1 TCF21 |
| Glaucoma (self-reported) |
6.40 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
CDKN2B CDKN2B-AS1 |
| Medication: Amlodipine |
4.30 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES TCF21 |
| Birth weight |
1.97 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
| Chronic bronchitis/emphysema (mother) |
2.72 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADAMTS7 |
| High blood pressure (siblings) |
3.34 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
| Forced vital capacity (FVC), Best measure |
0.76 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TCF21 |
| Body fat percentage |
0.98 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A3 |
| Arm fat-free mass (right) |
0.72 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A3 SORT1 |
| Pulse wave peak to peak time |
3.33 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES PHACTR1 |
| Medication for pain relief, constipation, heartburn |
3.27 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
PHACTR1 SORT1 |
| Medication: Blood pressure |
6.91 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES SLC22A1 TCF21 |
| Migraine (self-reported) |
4.89 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
PHACTR1 |
| Medication: Ibuprofen |
4.30 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
PHACTR1 SLC22A3 |
| Mean time to correctly identify matches |
1.43 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
| Heart disease (mother) |
16.14 |
8 |
3 |
6.7 |
0.96 |
2.7e-05 |
ADAMTS7 CDKN2B CDKN2B-AS1 FES PHACTR1 RP11-378J18.8 SLC22A1 SLC22A3 |
| Whole body fat mass |
1.05 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A3 |
| Leg fat mass (right) |
0.85 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A3 |
| Arm predicted mass (right) |
0.75 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A3 SORT1 |
| Pulse rate, automated reading |
3.46 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
RP11-378J18.8 SORT1 TCF21 |
| Alcohol intake frequency. |
1.54 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PHACTR1 |
| Comparative height size at age 10 |
0.99 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES SLC22A3 SORT1 |
| Chest pain or discomfort |
4.05 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
CDKN2B LPL |
| Medication: Aspirin |
15.75 |
8 |
5 |
11.1 |
0.99 |
2.2e-06 |
CDKN2B CDKN2B-AS1 FES LPL SLC22A1 SLC22A3 SORT1 TCF21 |
| Knee pain experienced in last month |
1.46 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PHACTR1 |
| Hypertension (Self-reported) |
6.87 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES SLC22A3 TCF21 |
| Illnesses of father: Heart disease |
29.23 |
11 |
8 |
17.8 |
0.99 |
4.0e-10 |
ADAMTS7 CDKN2B CDKN2B-AS1 FES LPL PHACTR1 RP11-378J18.8 SLC22A1 SLC22A3 SORT1 TCF21 |
| Smoking status: Previous |
1.68 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CDKN2B-AS1 |
| Whole body fat-free mass |
0.93 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES SLC22A3 SORT1 |
| Leg fat-free mass (right) |
1.06 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES SLC22A3 SORT1 |
| Handedness (chirality/laterality): Left-handed |
1.72 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
| Long-standing illness, disability or infirmity |
1.61 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CDKN2B |
| Diabetes diagnosed by doctor |
1.70 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A3 |
| Medication for cholesterol |
6.24 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
FES SLC22A3 SORT1 |
| Mineral and other dietary supplements |
2.73 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
| Breast cancer (self-reported) |
2.73 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CDKN2B |
| Asthma (self-reported) |
0.97 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
| Medication: Aspirin |
16.44 |
8 |
5 |
11.1 |
0.99 |
2.6e-06 |
CDKN2B CDKN2B-AS1 FES LPL SLC22A1 SLC22A3 SORT1 TCF21 |
| Illnesses of father: None of the above (group 1) |
9.91 |
4 |
2 |
4.4 |
-0.99 |
1.3e-02 |
CDKN2B CDKN2B-AS1 FES SLC22A3 |
| Forced expiratory volume in 1-second (FEV1), predicted percentage |
1.86 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADAMTS7 |
| Whole body water mass |
0.90 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES SLC22A3 SORT1 |
| Leg predicted mass (right) |
1.08 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES SLC22A3 SORT1 |
| Arm fat mass (left) |
1.09 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A3 |
| Mother's age at death |
2.03 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A1 |
| Eye problems/disorders: Glaucoma |
7.67 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
CDKN2B CDKN2B-AS1 |
| Medication: Blood pressure |
5.98 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
ADAMTS7 FES SLC22A3 |
| Supplements: Fish oil (including cod liver oil) |
2.39 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A3 |
| High cholesterol (Self-reported) |
24.34 |
6 |
4 |
8.9 |
0.81 |
5.2e-02 |
FES LPL RP11-378J18.8 SLC22A1 SLC22A3 SORT1 |
| Medication: Bendroflumethiazide |
5.10 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
ADAMTS7 FES TCF21 |
| Medication: Paracetamol |
1.52 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PHACTR1 |
| Medication: Lisinopril |
1.92 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
| Medication: Atorvastatin |
18.35 |
6 |
3 |
6.7 |
0.96 |
2.3e-03 |
CDKN2B CDKN2B-AS1 LPL SLC22A1 SLC22A3 SORT1 |
| Illnesses of father: High blood pressure |
4.98 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
| Ever smoked |
1.83 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
| Basal metabolic rate |
0.94 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES SLC22A3 SORT1 |
| Arm fat-free mass (left) |
0.73 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A3 SORT1 |
| Risk taking |
2.40 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
| Age started oral contraceptive pill |
1.95 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
| Diastolic blood pressure, automated reading |
6.37 |
4 |
2 |
4.4 |
0.97 |
3.4e-02 |
ADAMTS7 CDKN2B CDKN2B-AS1 FES |
| Vascular/heart problems diagnosed by doctor |
8.44 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
FES SLC22A3 TCF21 |
| Cholesterol lowering medication |
13.81 |
5 |
3 |
6.7 |
0.90 |
4.0e-02 |
CDKN2B LPL SLC22A1 SLC22A3 SORT1 |
| Medication: Omeprazole (e.g. Zanprol) |
1.20 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TCF21 |
| Pain experienced in last month |
1.43 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PHACTR1 |
| Basal cell carcinoma (self-reported) |
3.07 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CDKN2B |
| Heart attack/myocardial infarction (self-reported) |
25.82 |
10 |
8 |
17.8 |
0.98 |
3.2e-07 |
CDKN2B CDKN2B-AS1 FES LPL PHACTR1 RP11-378J18.8 SLC22A1 SLC22A3 SORT1 TCF21 |
| Heart disease (siblings) |
12.10 |
7 |
0 |
0.0 |
0.97 |
2.5e-04 |
ADAMTS7 CDKN2B-AS1 FES PHACTR1 SLC22A1 SLC22A3 SORT1 |
| Pack years of smoking |
6.31 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ADAMTS7 |
| Leg fat mass (left) |
0.75 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A3 |
| Arm predicted mass (left) |
0.78 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A3 SORT1 |